CTY vs DNTH: fair value comparison
City Therapeutics, Inc. and Dianthus Therapeutics, Inc. · Updated 2026-10-26
CTY has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. DNTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CTY currently ranks higher by quality score.
| CTY | DNTH | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $20.77 | $76.78 |
| 12-month range | — | $33.20–$115.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #183 of 302 Healthcare | #185 of 302 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Declining |
| RSI zone | — | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | — | The upper-middle quarter |
Full single-stock breakdowns: CTY fair value analysis · DNTH fair value analysis